#Spain #Implantica #GERD #RefluxStop #Burgos, Murcia

Implantica Boosts GERD Treatment with New RefluxStop Centers in Spain

In an exciting development for gastroesophageal reflux disease (GERD) treatment, Implantica AG has recently announced the onboarding of two new RefluxStop™ University Hospitals in Spain. This strategic move brings the total number of active centers to ten, marking significant progress in addressing a condition affecting approximately 1 billion people worldwide.

The cutting-edge RefluxStop™ device, designed to treat acid reflux, signals a new era in surgical procedures for GERD patients, particularly those who were previously unsuitable for traditional treatment options.

Expanding Access to Innovative Care

Dr. Mar Viana Miguel, noted foregut surgeon from Hospital Universitario Burgos in Castilla y León, has successfully conducted RefluxStop™ procedures this month, excitedly sharing, "We are awakening to a new era of surgical treatment for GERD. Many patients who struggled with ineffective medication now have a new, proven option with the RefluxStop™ procedure."

Similarly, Dr. Inmaulada Navarro of the Universitario Santa Lucia Hospital expressed gratitude towards her unit’s management for embracing this technology, noting the impressive results from clinical studies involving over 1,000 patients across Europe. The introduction of RefluxStop™ in Spain aligns with the aim to provide lasting surgical solutions for GERD patients who don’t respond to Proton Pump Inhibitors (PPIs).

A Groundbreaking Solution

The RefluxStop™ implant represents a significant advancement in the treatment of GERD compared to older surgical techniques that often entailed wrapping the esophagus. This device works by restoring the function of the lower esophageal sphincter without exerting pressure on the esophagus, thus mitigating common complications like difficulty swallowing and discomfort.

Dr. Peter Forsell, creator of RefluxStop™ and CEO of Implantica, commented on the overwhelming acceptance of the technology in Spain. “Around 15% of adults in Spain suffer from GERD, leading to extensive use of anti-reflux medications. We are looking forward to collaborating with esteemed surgeons and expanding our network to meet the demand for effective treatment,” he stated, highlighting the positive implications for future patients.

Looking Ahead

The ongoing partnership with top surgeons in Spain reflects Implantica's commitment to improving GERD treatment. As more centers are set to adopt the RefluxStop™ technology, the company aims to offer an innovative remedy to millions of patients grappling with GERD symptoms. The feedback from medical professionals emphasizes the transformative potential of this groundbreaking procedure.

Implantica is on a mission not only to enhance individual patient care but also to potentially reshape the landscape of GERD treatment across Europe. With new centers opening, the anticipation rises over the benefits the RefluxStop™ technology will provide to numerous patients in need.

By prioritizing effective, less invasive options, Implantica’s advancements signify not only a technological breakthrough but also a hopeful future for individuals suffering from chronic acid reflux. The expansion of RefluxStop™ Centers of Excellence in Spain illustrates a growing commitment to patient-centered care in the field of medical technology, reinforcing the importance of innovation in healthcare.